Polaryx Therapeutics, Inc. (PLYX) stock
PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.61+0.01 (+0.63%)
Close on Nov 18, 2026Market cap $80.25MP/E –Yield –
Polaryx Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Polaryx Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$7.58M. For fiscal 2025 it was -$7.82M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.82M | – |
| FY2024 | Dec 31, 2024 | -$4.35M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.33M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.96M | – |
| Q4 FY2025 | Dec 31, 2025 | -$911.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$974.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$884.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.05M | – |
See a number that looks wrong?